These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16940091)

  • 21. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
    Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
    J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.
    Namba K; Naka K; Dansako H; Nozaki A; Ikeda M; Shiratori Y; Shimotohno K; Kato N
    Biochem Biophys Res Commun; 2004 Oct; 323(1):299-309. PubMed ID: 15351737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
    Watashi K
    Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro.
    Weng L; Tian X; Gao Y; Watashi K; Shimotohno K; Wakita T; Kohara M; Toyoda T
    Biochim Biophys Acta; 2012 Dec; 1820(12):1886-92. PubMed ID: 22954804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
    Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
    Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific inhibition of hepatitis C virus replication by cyclosporin A.
    Nakagawa M; Sakamoto N; Enomoto N; Tanabe Y; Kanazawa N; Koyama T; Kurosaki M; Maekawa S; Yamashiro T; Chen CH; Itsui Y; Kakinuma S; Watanabe M
    Biochem Biophys Res Commun; 2004 Jan; 313(1):42-7. PubMed ID: 14672695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
    Chang JH; Kato N; Muroyama R; Taniguchi H; Guleng B; Dharel N; Shao RX; Tateishi K; Jazag A; Kawabe T; Omata M
    Liver Int; 2010 Feb; 30(2):311-8. PubMed ID: 19840259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.
    Ciesek S; Steinmann E; Wedemeyer H; Manns MP; Neyts J; Tautz N; Madan V; Bartenschlager R; von Hahn T; Pietschmann T
    Hepatology; 2009 Nov; 50(5):1638-45. PubMed ID: 19821520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion.
    Anderson LJ; Lin K; Compton T; Wiedmann B
    Virol J; 2011 Jun; 8():329. PubMed ID: 21711559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.
    Watashi K; Ishii N; Hijikata M; Inoue D; Murata T; Miyanari Y; Shimotohno K
    Mol Cell; 2005 Jul; 19(1):111-22. PubMed ID: 15989969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diverse effects of cyclosporine on hepatitis C virus strain replication.
    Ishii N; Watashi K; Hishiki T; Goto K; Inoue D; Hijikata M; Wakita T; Kato N; Shimotohno K
    J Virol; 2006 May; 80(9):4510-20. PubMed ID: 16611911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.
    Arai M; Tsukiyama-Kohara K; Takagi A; Tobita Y; Inoue K; Kohara M
    Biochem Biophys Res Commun; 2014 May; 448(1):56-62. PubMed ID: 24751518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.
    Liu WL; Su WC; Cheng CW; Hwang LH; Wang CC; Chen HL; Chen DS; Lai MY
    J Infect Dis; 2007 Aug; 196(3):425-34. PubMed ID: 17597457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of the interferon alpha response against hepatitis C virus replicons.
    Guo JT; Sohn JA; Zhu Q; Seeger C
    Virology; 2004 Jul; 325(1):71-81. PubMed ID: 15231387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
    Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
    Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.
    Flisiak R; Horban A; Gallay P; Bobardt M; Selvarajah S; Wiercinska-Drapalo A; Siwak E; Cielniak I; Higersberger J; Kierkus J; Aeschlimann C; Grosgurin P; Nicolas-Métral V; Dumont JM; Porchet H; Crabbé R; Scalfaro P
    Hepatology; 2008 Mar; 47(3):817-26. PubMed ID: 18302285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conventional protein kinase C inhibition prevents alpha interferon-mediated hepatitis C virus replicon clearance by impairing STAT activation.
    Fimia GM; Evangelisti C; Alonzi T; Romani M; Fratini F; Paonessa G; Ippolito G; Tripodi M; Piacentini M
    J Virol; 2004 Dec; 78(23):12809-16. PubMed ID: 15542633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon.
    Aus dem Siepen M; Oniangue-Ndza C; Wiese M; Ross S; Roggendorf M; Viazov S
    Virus Res; 2007 Apr; 125(1):109-13. PubMed ID: 17254660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
    Coelmont L; Kaptein S; Paeshuyse J; Vliegen I; Dumont JM; Vuagniaux G; Neyts J
    Antimicrob Agents Chemother; 2009 Mar; 53(3):967-76. PubMed ID: 19104013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.